Research and development

Our ambitious programmes aim to substantially reduce global epidemic and pandemic risk. CEPI’s priority diseases include Chikungunya, COVID-19, Ebola, Lassa Fever, MERS, Mpox, Nipah, Rift Valley Fever, and novel viral threats with epidemic or pandemic potential (also known as “Disease X”).

A team of scientists working on vaccine creating in a modern laboratory
female scientist holding a pipette looking at equipment

Enabling science

From biological standards to preclinical models, CEPI supports enabling science activities to accelerate the development of safe and effective vaccines.

Read more
scientist in lab coat holding a pipette and a glass vial

Biosecurity

CEPI’s inaugural Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse.

Read more
Researchers in the field

CEPI Technical Resources Hub

CEPI’s Technical Resources Hub is an open-access platform that aims to equip vaccine researchers, developers and funders with tools, methods, and knowledge to advance epidemic preparedness innovations.

Read more
blue illustration including AI and R&D icons

Artificial intelligence

AI is revolutionising how science can protect the world and its people against the threat of infectious disease outbreaks. Learn how CEPI is harnessing the power of AI to transform vaccine development for future epidemics or pandemics.

Read more

Biosecurity

CEPI’s inaugural Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse.

Read more
scientist in lab coat holding a pipette and a glass vial

Call for Proposals

We invite innovators worldwide to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.

Apply now
University of Queensland scientists in a lab

Latest News

healthcare workers talking to trial participant
News

First participant vaccinated in pivotal Phase 2/3 Bundibugyo vaccine trial in DRC

First participant vaccinated in a Phase 1 clinical study of the Oxford Lassa vaccine. Credit: Kintampo Health Research Centre
CEPI

First participants vaccinated with Oxford's CEPI-backed Lassa shot in Ghana

speakers on stage in chairs in front of screen talking
Blog

CEPI and World Bank Group partner to strengthen sustainable vaccine manufacturing in ASEAN

three white circular icons on blue background
Statement

Final preparations underway for pivotal Phase 2/3 Bundibugyo vaccine trial